Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 23 peer-reviewed journal articles Updated
Medical Genetics · CDKL5 Deficiency Disorder

The Genetics and Biology of CDD

At a Glance

CDKL5 deficiency disorder is caused by a CDKL5 gene variant that disrupts a protein needed for brain-cell connections and communication. X-inactivation, mosaicism, and other biology can make symptoms vary, so a variant cannot predict one child’s exact future.

While the diagnosis of CDKL5 Deficiency Disorder (CDD) can feel overwhelming, understanding the “why” behind your child’s symptoms can be an empowering step. At its core, CDD is a biological condition caused by a change in a single gene that plays a vital role in how the brain builds itself and communicates [1].

Glossary of Genetic Terms

  • Missense Variant: A genetic “typo” that substitutes one amino acid for another in the protein.
  • Nonsense or Frameshift Variant: A change that usually causes the protein to be cut short, severely reducing its function.
  • Kinase Domain: The active “working” section of the CDKL5 protein.
  • C-terminal Tail: The end segment of the CDKL5 protein.
  • X-inactivation: The process where one X chromosome is turned off in female cells.

The Role of the CDKL5 Protein

The CDKL5 gene provides the instructions for making a protein that acts as a kinase. Think of a kinase like a biological “master switch” or a project manager in a cell [2]. Its job is to add a small chemical tag (phosphorylation) to other proteins, which turns them on or off [2][3].

In the brain, this CDKL5 protein is essential for:

  • Building Connections: It helps neurons (brain cells) grow long branches and develop synapses, the specialized points where cells pass signals to one another [4][5].
  • Maintaining Balance: It helps regulate the balance between “go” signals (excitation) and “stop” signals (inhibition) [6][7].
  • Cell Transport: It helps move important “cargo” and nutrients throughout the long, complex branches of the brain cells [4][8].

When the CDKL5 gene has a variant (a mutation or “typo” in the genetic code), the protein is either produced with reduced function, altered, or not made at all [9]. Without this “manager” on the job, the brain’s development and communication become disrupted, leading to the seizures and developmental delays seen in CDD [10][11].

Genetics: X-Chromosomes and Inactivation

The CDKL5 gene is located on the X chromosome [12]. Because biological females have two X chromosomes and biological males have only one, the disorder presents slightly differently in each:

  • In Females: In every cell of a female’s body, one of the two X chromosomes is “turned off” in a process called X-chromosome inactivation (XCI) [13]. This means that in a girl with CDD, some cells will use the healthy gene, while others use the variant gene [13]. The ratio of “healthy” to “variant” cells can vary significantly and differ between tissues. Importantly, an X-inactivation blood test cannot reliably predict how the brain is affected.
  • In Males: Because males have only one X chromosome, a variant in that gene usually affects every cell in the body [12]. However, some males have mosaicism, which means the genetic change happened after fertilization and is only present in a percentage of their cells [14]. Mosaicism in males is often associated with milder motor and visual symptoms, though it does not usually prevent seizures [14][15].

Understanding Genotype and Phenotype

Doctors often talk about the genotype (the specific genetic change) and the phenotype (the actual symptoms and abilities a child has). While research has found some broad patterns, these are probabilistic, not absolute guarantees [13].

Generally, variants that severely disrupt the protein (like nonsense or frameshift mutations) or those located in the “kinase domain” are often associated with more severe symptoms at a cohort level [13][16]. Conversely, variants located at the very end of the gene (the C-terminal tail) are sometimes associated with milder outcomes in studies [17][18]. However, because of factors like XCI, mosaicism, and each child’s unique biology, two children with the exact same variant can have very different paths [13][19].

Why CDD is Not Rett Syndrome

In the past, CDD was often called the “early-onset seizure variant” of Rett syndrome because both involve the X chromosome and share similar symptoms [20]. However, we now know they are distinct biological conditions:

  • CDD is caused by the CDKL5 gene, while Rett syndrome is caused by the MECP2 gene [21][22].
  • In CDD, seizures usually start very early (often in the first 3 months), whereas in Rett syndrome, seizures often appear later [20][22].
  • Children with Rett syndrome typically experience a classic period of “regression” where they lose skills they previously had; in CDD, development is usually severely delayed from the beginning, though plateauing or loss of skills can still occasionally occur [20][23].

While the biology of CDD is complex, understanding that your child’s challenges are rooted in these fundamental cellular processes can help focus your conversations with specialists on the most effective ways to support their brain’s unique way of working.

Common questions in this guide

What causes CDKL5 deficiency disorder?
CDD is caused by a variant, or change, in the CDKL5 gene. The gene normally makes a kinase, a protein that helps control activity in other proteins, and this supports brain-cell growth, connections, signal balance, and transport. When the protein is altered, reduced, or missing, early seizures and developmental delays can result.
Can the type or location of a CDKL5 variant predict how severe CDD will be?
Some studies find that variants that stop the protein early or affect its working kinase region are associated with more severe features, while variants near the protein’s tail end may be associated with milder outcomes. These are group-level patterns, not predictions for one child. X-inactivation, mosaicism, and individual biology can make children with the same variant develop differently.
Can an X-inactivation blood test predict how CDD will affect my daughter?
Not reliably. In females, cells can use either the healthy or altered X chromosome, and the balance can differ between blood and brain tissue. A blood result therefore cannot show exactly how the brain is affected or determine a child’s future on its own.
How can CDD differ in females and males?
Females have two X chromosomes, so X-inactivation creates a mixture of cells using the healthy or altered CDKL5 gene. Males usually have one X chromosome, so a variant can affect most cells; mosaicism can limit the change to some cells and may be linked with milder motor or visual symptoms. Seizures can still occur in males with mosaicism.
Is CDKL5 deficiency disorder the same as Rett syndrome?
No. CDD is caused by changes in CDKL5, whereas Rett syndrome is caused by changes in MECP2. CDD seizures usually begin much earlier, often in the first three months, and development is generally delayed from the beginning, while Rett syndrome more often includes a later loss of previously learned skills.
Why can children with the same CDKL5 variant have different developmental outcomes?
A variant provides useful information but cannot determine a child’s exact developmental path. Differences in X-inactivation, mosaicism, which tissues carry the variant, and other individual biological factors can change how much working CDKL5 protein is available. Your child’s clinicians and genetic counselor can interpret the result in the context of their symptoms and development.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.What is the specific name and type of my child’s CDKL5 variant (e.g., missense, nonsense, or frameshift)?
  2. 2.Is the variant located within the kinase domain or the C-terminal tail of the gene?
  3. 3.In our case, is there evidence of 'mosaicism' or 'X-inactivation skewing' that might influence how the condition progresses?
  4. 4.Based on the current literature, have other children with this specific variant been identified, and what did their developmental path look like?
  5. 5.Why was CDD formerly considered a variant of Rett syndrome, and what specific features distinguish my child's diagnosis from Rett?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (23)
  1. 1

    International Consensus Recommendations for the Assessment and Management of Individuals With CDKL5 Deficiency Disorder.

    Amin S, Monaghan M, Aledo-Serrano A, et al.

    Frontiers in neurology 2022; (13()):874695 doi:10.3389/fneur.2022.874695.

    PMID: 35795799
  2. 2

    Chemical genetic identification of CDKL5 substrates reveals its role in neuronal microtubule dynamics.

    Baltussen LL, Negraes PD, Silvestre M, et al.

    The EMBO journal 2018; (37(24)) doi:10.15252/embj.201899763.

    PMID: 30266824
  3. 3

    CDKL5 deficiency predisposes neurons to cell death through the deregulation of SMAD3 signaling.

    Fuchs C, Medici G, Trazzi S, et al.

    Brain pathology (Zurich, Switzerland) 2019; (29(5)):658-674 doi:10.1111/bpa.12716.

    PMID: 30793413
  4. 4

    CDKL5 regulates the initiation of retrograde axonal transport through CLIP170-dynactin complex formation.

    Baldin S, Carmone C, Valetti G, et al.

    The FEBS journal 2026; (293(2)):456-474 doi:10.1111/febs.70230.

    PMID: 40847610
  5. 5

    CDKL5 modulates the plasticity of excitatory synapses via liquid-liquid phase separation.

    Li M, Zhu Z, Li D, et al.

    Proceedings of the National Academy of Sciences of the United States of America 2026; (123(8)):e2511123123 doi:10.1073/pnas.2511123123.

    PMID: 41706882
  6. 6

    Loss of CDKL5 Causes Synaptic GABAergic Defects That Can Be Restored with the Neuroactive Steroid Pregnenolone-Methyl-Ether.

    De Rosa R, Valastro S, Cambria C, et al.

    International journal of molecular sciences 2022; (24(1)) doi:10.3390/ijms24010068.

    PMID: 36613509
  7. 7

    A GABAB receptor antagonist rescues functional and structural impairments in the perirhinal cortex of a mouse model of CDKL5 deficiency disorder.

    Gennaccaro L, Fuchs C, Loi M, et al.

    Neurobiology of disease 2021; (153()):105304 doi:10.1016/j.nbd.2021.105304.

    PMID: 33621640
  8. 8

    Pregnenolone-methyl-ether enhances CLIP170 and microtubule functions improving spine maturation and hippocampal deficits related to CDKL5 deficiency.

    Barbiero I, Zamberletti E, Tramarin M, et al.

    Human molecular genetics 2022; (31(16)):2738-2750 doi:10.1093/hmg/ddac067.

    PMID: 35348691
  9. 9

    Two Novel Variants Affecting CDKL5 Transcript Associated with Epileptic Encephalopathy.

    Neupauerová J, Štěrbová K, Vlčková M, et al.

    Genetic testing and molecular biomarkers 2017; (21(10)):613-618 doi:10.1089/gtmb.2017.0110.

    PMID: 28872899
  10. 10

    Epilepsy-Related CDKL5 Deficiency Slows Synaptic Vesicle Endocytosis in Central Nerve Terminals.

    Kontaxi C, Ivanova D, Davenport EC, et al.

    The Journal of neuroscience : the official journal of the Society for Neuroscience 2023; (43(11)):2002-2020 doi:10.1523/JNEUROSCI.1537-22.2023.

    PMID: 36759195
  11. 11

    Excitatory Cortical Neurons from CDKL5 Deficiency Disorder Patient-Derived Organoids Show Early Hyperexcitability Not Identified in Neurogenin2 Induced Neurons.

    Glass MR, Whye D, Anderson NC, et al.

    bioRxiv : the preprint server for biology 2024; doi:10.1101/2024.11.11.622878.

    PMID: 39605742
  12. 12

    CDKL5 deficiency disorder in males: Five new variants and review of the literature.

    Siri B, Varesio C, Freri E, et al.

    European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society 2021; (33()):9-20 doi:10.1016/j.ejpn.2021.04.007.

    PMID: 33989939
  13. 13

    Exploring genotype-phenotype relationships in the CDKL5 deficiency disorder using an international dataset.

    MacKay CI, Wong K, Demarest ST, et al.

    Clinical genetics 2021; (99(1)):157-165 doi:10.1111/cge.13862.

    PMID: 33047306
  14. 14

    CDKL5 deficiency causes epileptic seizures independent of cellular mosaicism.

    Takahashi S, Takeguchi R, Tanaka R, et al.

    Journal of the neurological sciences 2022; (443()):120498 doi:10.1016/j.jns.2022.120498.

    PMID: 36417806
  15. 15

    Epilepsy phenotype and developmental outcome in girls with mosaicism in X-linked neurodevelopmental disorders.

    Carapancea E, Eizadkhah D, Santalucia R, et al.

    Epileptic disorders : international epilepsy journal with videotape 2025; (27(5)):1011-1020 doi:10.1002/epd2.70058.

    PMID: 40587154
  16. 16

    CDKL5 variants: Improving our understanding of a rare neurologic disorder.

    Hector RD, Kalscheuer VM, Hennig F, et al.

    Neurology. Genetics 2017; (3(6)):e200 doi:10.1212/NXG.0000000000000200.

    PMID: 29264392
  17. 17

    The CDKL5 kinase undergoes liquid-liquid phase separation driven by a serine-rich C-terminal region.

    Boggio Bozzo S, Dell'Oca M, Vaglietti S, et al.

    Life science alliance 2026; (9(5)) doi:10.26508/lsa.202503402.

    PMID: 41807047
  18. 18

    Wide range of phenotypic severity in individuals with late truncations unique to the predominant CDKL5 transcript in the brain.

    Keehan L, Haviland I, Gofin Y, et al.

    American journal of medical genetics. Part A 2022; (188(12)):3516-3524 doi:10.1002/ajmg.a.62940.

    PMID: 35934918
  19. 19

    The natural history of CDKL5 deficiency disorder into adulthood.

    Aledo-Serrano A, Lewis-Smith D, Leonard H, et al.

    medRxiv : the preprint server for health sciences 2025; doi:10.1101/2025.01.12.24318239.

    PMID: 39867409
  20. 20

    Comparison of Core Features in Four Developmental Encephalopathies in the Rett Natural History Study.

    Cutri-French C, Armstrong D, Saby J, et al.

    Annals of neurology 2020; (88(2)):396-406 doi:10.1002/ana.25797.

    PMID: 32472944
  21. 21

    Cyclin-Dependent Kinase-Like 5 Deficiency Disorder: Clinical Review.

    Olson HE, Demarest ST, Pestana-Knight EM, et al.

    Pediatric neurology 2019; (97()):18-25 doi:10.1016/j.pediatrneurol.2019.02.015.

    PMID: 30928302
  22. 22

    Rett and Rett-related disorders: Common mechanisms for shared symptoms?

    D'Mello SR

    Experimental biology and medicine (Maywood, N.J.) 2023; (248(22)):2095-2108 doi:10.1177/15353702231209419.

    PMID: 38057990
  23. 23

    CDKL5 deficiency disorder: clinical features, diagnosis, and management.

    Leonard H, Downs J, Benke TA, et al.

    The Lancet. Neurology 2022; (21(6)):563-576 doi:10.1016/S1474-4422(22)00035-7.

    PMID: 35483386

This page is for informational purposes only and does not constitute medical advice. A clinical geneticist, neurologist, or genetic counselor should interpret your child’s CDKL5 variant and developmental outlook.

Get notified when new evidence is published on CDKL5-deficiency disorder.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.